

Substitute Form PTO-1449 (Modified)  <b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)  (37 CFR §1.98(b))	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. <b>14503-0005US1</b>	Application No. <b>10/567,266</b>
	Applicant <b>Eichner et al.</b>		
	Filing Date <b>05-29-2008</b>	Group Art Unit <b>1623</b>	

<b>U.S. Patent Documents</b>							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	1	2002/0065410	05/30/2002	Antrim			
	2	2003/0087877	05/08/2003	Calias et al.			
	3	2003/0191291	10/09/2003	Kochendoerfer et al.			
	4	2006/0194940	08/31/2006	Kozlowski			
	5	2007/134197	06/14/2007	Eichner et al.			
	6	2008/0274948	11/06/2008	Eichner et al.			
	7	2009/0091549	04/09/2009	Matsumoto et al.			
	8	3, 226, 395	12/28/1965	Schimmelschmidt et al.			
	9	4, 454, 161	06/12/1984	Okada et al.			
	10	4,939, 239	07/03/1990	Matsushashi et al.			
	11	5, 073, 628	12/17/1991	Matsushashi et al.			
	12	5, 110, 909	05/05/1992	Dellacherie et al.			
	13	5, 420, 105	05/30/1995	Gustavson et al.			
	14	5, 736, 533	04/07/1998	Simon et al.			
	15	5, 770, 645	06/23/1998	Stamler et al.			
	16	5, 840, 900	11/24/1998	Greenwald et al.			
	17	5, 977, 163	11/02/1999	Li et al.			
	18	5, 981, 507	11/09/1999	Josephson et al.			
	19	5, 990, 237	11/23/1999	Bentley et al.			
	20	6, 172, 208	01/09/2001	Cook			
	21	6, 395, 266	05/28/2002	Martinez et al.			
	22	6, 417, 347	07/09/2002	Herrmann et al.			
	23	6,451, 337	09/17/2002	Smith et al.			
	24	6,544, 503	04/08/2003	Vanderhoff et al.			
	25	6, 596, 861	07/22/2003	Moreau			
	26	6, 624, 142	09/23/2003	Greenwald et al.			
	27	6, 916, 962	07/12/2005	Rosen et al.			

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)  <b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)  (37 CFR §1.98(b))	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. <b>14503-0005US1</b>	Application No. <b>10/567,266</b>
	Applicant <b>Eichner et al.</b>		
	Filing Date <b>05-29-2008</b>	Group Art Unit <b>1623</b>	

<b>U.S. Patent Documents</b>							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	28	6, 596, 135	07/22/2003	Mitsui			
	29	7, 157, 546	01/02/2007	Kozlowski			
	30	7, 279, 176	10/09/2007	West et al.			
	31	7, 538, 092	05/26/2009	Orlando et al.			
	32	7, 541, 328	06/02/2009	Hemberger et al.			
	33	7, 815, 893	10/19/2010	Zander et al.			
	34	7, 816, 516	10/19/2010	Sommermeyer et al.			

<b>Foreign Patent Documents or Published Foreign Patent Applications</b>								
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	35	5238393	06/23/1994	AU				
	36	2,110,543	06/10/1994	CA				
	37	279 486	06/06/1990	DD				
	38	100 41 541	03/14/2002	DE				
	39	101 12 825	10/02/2002	DE				
	40	101 26 158	12/12/2002	DE				
	41	101 29 369	03/06/2003	DE				
	42	101 35 694	02/06/2003	DE				
	43	101 55 098	05/22/2003	DE				
	44	102 09 821	09/25/2003	DE				
	45	102 17 994	11/06/2003	DE				
	46	102 54 745	06/03/2004	DE				
	47	102 56 558	12/04/2002	DE				
	48	196 28 705	01/15/1998	DE				
	49	198 08 079	08/26/1999	DE				
	50	22 33 977	02/01/1973	DE				
	51	26 07 706	01/04/1977	DE				

Examiner Signature	Date Considered
--------------------	-----------------

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Form PTO-1449 (Modified)  <b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)  (37 CFR §1.98(b))	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. <b>14503-0005US1</b>	Application No. <b>10/567,266</b>
	Applicant <b>Eichner et al.</b>		
	Filing Date <b>05-29-2008</b>		Group Art Unit <b>1623</b>

<b>Foreign Patent Documents or Published Foreign Patent Applications</b>								
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	52	26 16 086	11/03/1977	DE				
	53	30 29 307	03/04/1982	DE				
	54	35 01 616	07/17/1986	DE				
	55	38 36 600	05/03/1990	DE				
	56	41 30 807	03/18/1993	DE				
	57	0 338 916	10/25/1989	EP				
	58	0 661 294	07/05/1995	EP				
	59	0 806 140	11/12/1997	EP				
	60	1 496 076	01/12/2005	EP				
	61	1, 591, 467	11/02/2005	EP				
	62	1, 660, 134	12/29/2010	EP				
	63	2 070 950	06/17/2009	EP				
	64	1, 665 06	02/17/2010	IL				
	65	10287554	10/27/1998	JP				
	66	2001-294601	10/23/2001	JP				
	67	00/18893	04/06/2000	WO				
	68	00/66633	11/09/2000	WO				
	69	01/78682	10/25/2001	WO				
	70	01/83522	11/08/2001	WO				
	71	01/93862	12/13/2001	WO				
	72	97/30148	08/21/1997	WO				
	73	02/28841	04/11/2002	WO				
	74	03/049699	06/19/2003	WO				
	75	04/022630	03/18/2004	WO				
	76	05/072778	08/11/2005	WO				
	77	05/083103	09/09/2005	WO				
	78	05/092369	10/06/2005	WO				

Examiner Signature	Date Considered
--------------------	-----------------

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Form PTO-1449 (Modified)  <b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)  (37 CFR §1.98(b))	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. <b>14503-0005US1</b>	Application No. <b>10/567,266</b>
	Applicant <b>Eichner et al.</b>		
	Filing Date <b>05-29-2008</b>	Group Art Unit <b>1623</b>	

<b>Foreign Patent Documents or Published Foreign Patent Applications</b>								
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	79	05/112954	12/01/2005	WO				
	80	07/053292	05/10/2007	WO				
	81	10/042638	04/15/2010	WO				
	82	92/11037	07/09/1992	WO				
	83	93/24476	12/09/1993	WO				
	84	97/42225	11/13/1997	WO				
	85	98/05689	02/12/1998	WO				
	86	98/07713	02/26/1998	WO				
	87	98/14212	04/09/1998	WO				
	88	98/14215	04/09/1998	WO				
	89	99/17783	04/15/1999	WO				

<b>Other Documents (include Author, Title, Date, and Place of Publication)</b>		
Examiner Initial	Desig. ID	Document
	90	ALAGON et al., "Activation of Polysaccharides with 2-lminothiolane and its uses," <u>Biochem.</u> 19:4341-4345 (1980)
	91	ANNO et al., "Basic of Sugar chemistry," pp. 1-5 (1995) (w/ translation)
	92	BALAZY et al., "S-Nitroglutathione, a Product of the Reaction between Peroxynitrite and Glutathione that Generates Nitric Oxide," <u>J. Biol. Chem.</u> 273(48):32009-32015 (1998)
	93	BAYER et al., "The Avidin-Biotin Complex in Affinity Cytochemistry," <u>Meth Enzymol.</u> 62:308-315 (1979)
	94	BERNARDES et al. "The Direct Formation of GlycosylThiols from Reducing Sugars Allows One-Pot Protein Glycoconjugation," <u>Angew Chem.</u> 118:4111-4115 (2006)
	95	BESHEER et al., "Enzymatically Catalyzed HES Conjugation Using Microbial Transglutaminase:Proof of Feasibility," <u>J. Pharm. Sci.</u> 98(11):4420-4428 (2009)
	96	BOYER et al., "Reaction in Biphasic Water/Organic Solvent System in the Presence of Surfactant:Inverse Phase Transfer Catalysis versus Interfacial Catalysis," <u>Tetrahedron</u> 56:303-307 (2000)
	97	CAREY AND SUNDBERG, "Organische Chemie," VCH Verlagsgesellschaft mbH, Weinheim (DE) (1995)
	98	CAVALLARO et al., "Folate-mediated targeting of polymeric conjugates of gemcitabine," <u>Int. J. Pharmaceut.</u> 307:258-269 (2006)
	99	ETRYCH et al., "New HPMA Copolymers containing doxorubicin bound via pH-sensitive linkage:synthesis and preliminary in vitro and in vivo biological properties," <u>J. Controlled Release</u> 73:89-102 (2001)

Examiner Signature	Date Considered
--------------------	-----------------

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Form PTO-1449 (Modified)  <b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)  (37 CFR §1.98(b))	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 14503-0005US1	Application No. 10/567,266
	Applicant Eichner et al.		
	Filing Date 05-29-2008		Group Art Unit 1623

<b>Other Documents (include Author, Title, Date, and Place of Publication)</b>		
Examiner Initial	Desig. ID	Document
	100	GERWECH et al., "Tumor pH controls the in vivo efficacy of weak acid and base chemotherapeutics," <u>Mol. Cancer Ther.</u> 5(5):1275-2179 (2006)
	101	GLEDERBLOM et al., "Cremophor El:the drawbacks and advantages of vehicle selection for drug formulation," <u>Eur. J. Cancer</u> 37:1590-1598 (2001)
	102	GREENWALD et al., "Drug Delivery Systems:Water Soluble Taxol 2'-Poly (ethylene glycol) Ester Prodrugs- Design and in Vivo Effectiveness," <u>J. Med. Chem.</u> 39:424-431 (1996)
	103	GRIECO et al., "Favored Reduction of $\alpha$ -Chlorosilanes vs. $\alpha$ -Chloroalkanes with Tri-n-butyltin Hydride," <u>J. Org. Chem.</u> 43(6):1285 (1978)
	104	HAMILTON et al., Characterization of Human Ovarian Carcinoma Cell Line (NIH:OVCAR-3) with Androgen and Estrogen Receptors," <u>Cancer Res.</u> 43:5379-5389 (1983)
	105	HARADA et al. "Carrier and dose effects on the pharmacokinetics of T-0128, a camptothecin analogue-carboxymethyl dextran conjugate, in non-tumor-and tumor-bearing rats," <u>J. Controlled Release</u> 71:71-86 (2001)
	106	HARADA et al., Determinants for the drug release from T-0128, camptothecin analogue-carboxymethyl dextran conjugate," <u>J. Controlled Release</u> 69:399-412 (2000)
	107	HEINDEL et al, "Hydrazide Pharmaceuticals as Conjugates to Polyaldehyde Dextran" <u>Bioconjugate Chem.</u> 1:77-82 (1990)
	108	HEITZMANN AND RICHARDS, "Use of the Avidin-Biotin Complex for Specific Staining of Biological Membranes in Electron Microscopy," <u>Proc. Natl. Acad. Sci. USA</u> 71(9):3537-3561 (1974)
	109	JUNGHEINRICH et al., "Pharmacokinetics of Hydroxyethyl Starch," <u>Clin. Pharmacokinet.</u> 44 (7):681-699 (2005)
	110	KATSUMI et al., "Development of Polyethylene Glycol-Conjugated Poly-S Nitrosated Serum Albumin, a Novel S-Nitrosothiol for Prolonged Delivery of Nitric Oxide in the Blood Circulation in Vivo," <u>J. Pharmacol. Exp. Ther.</u> 314(3):1117-1124 (2005)
	111	KINSTLER et al., "Characterization and Stability of N-terminally PEGylated rhG-CSF," <u>Pharmaceut. Res.</u> 13 (7):996-1002 (1996)
	112	KLEINE-TEBBE et al., "Allergen Immunotherapy – A Position Paper of the German Society for Allergology and Clinical Immunology," <u>Pneumologie</u> 55:438-444 (2001) (w/English summary)
	113	KULICKE et al., "Measurements of the Refractive Index Increment on Hydroxyethyl Starch as a Basis for Absolute Molecular Weight Determinations," <u>Starch</u> 43(10):392-396 (1991)
	114	LAINE et al., "Polyethylene Glycol Nephrotoxicity Secondary to Prolonged High-Dose Intravenous Lorazepam," <u>Ann. Pharmacother.</u> 29:1110-1114 (1995)
	115	LEE et al., "Functional Polymers for Layer-by-Layer Construction of Multilayer via Chemoselective Immobilization," <u>Macromolecules</u> 37:1849-1856 (2004)
	116	LEE, Ed., <u>Peptide and Protein Drug Delivery</u> , Marcel Dekker, 1991, Page 65
	117	LEWIS et al., "The phase transfer catalysed synthesis of isoflavone-O-glucosides," <u>J. Chem. Soc. Perkins Trans.</u> 1:2481-2484 (1998)
	118	LEWIS AND WÄHÄLÄ, "Regiospecific 4'-O- $\beta$ -glucosidation of isoflavones," <u>Tetrahedron Lett.</u> 39(51):9559-9562 (1998)
	119	LIEBER et al., "A Continuous Tumor-Cell Line From a Human Lung Carcinoma with Properties of Type II Alveolar Epithelial Cells," <u>Int. J. Cancer</u> 17:62-70 (1976)

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)  <b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)  (37 CFR §1.98(b))	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 14503-0005US1	Application No. 10/567,266
	Applicant Eichner et al.		
	Filing Date 05-29-2008		Group Art Unit 1623

<b>Other Documents (include Author, Title, Date, and Place of Publication)</b>		
Examiner Initial	Desig. ID	Document
	120	LIPKE et al., "Localized Delivery of Nitric Oxide from Hydrogels Inhibits Neointima Formation in Rat Carotid Ballon Injury Model," <u>Acta Biomaterialia</u> 1:597-606 (2005)
	121	LUND et al., Assessment of methods for covalent binding of nucleic acids to magnetic beads, Dynabeads, and the characteristics of the bound nucleic acids in hybridization reactions," <u>Nucl. Acids Res.</u> 16(22):10861-10880 (1988)
	122	MEGSON et al., "Inhibition of Human Platelet Aggregation by a Novel S-Nitrosothiol is Abolished by Hemoglobin and Red Blood Cell in vitro:Implications for Anti-Thrombotic Therapy," <u>Brit. J. Pharmacol.</u> 131:1391-1398 (2000)
	123	NATHAN et al., "Strategies for Covalent Attachment of Doxorubicin to Ply (PEG-Lys), a New Water Soluble Poly (etherurethane)," <u>J. Bioactive Compatible Polymers</u> , 9:239-251 (1994)
	124	Organikum, Organisch-chemisches Grundpraktikum, 1984, <u>VEB Deutscher Verlag der Wissenschaften</u> , p. 472 (with verified English translation)
	125	PASUT et al., "Antitumoral activity of PEG-gemcitabine prodrugs targeted by folic acid," <u>J. Controlled Release</u> 127(3):239-248 (2008)
	126	PERI et al., "Chemo- and Stereoselective Glycosylation of Hydroxylamino Derivatives:A Versatile Approach to Glycoconjugates," <u>Tetrahedron</u> 54:12269-12278 (1998)
	127	PETERSON, the physiological inhibitors of blood coagulation and fibrinolysis, elsevier/ north-holland biomedical press 1979, TOC
	128	REYNOLDS et al., "S-nitrosohemoglobin deficiency:A mechanism for loss of physiological activity in banked blood," <u>Proc. Natl. Acad. Sci. USA</u> 104(43):17058-17062 (2007)
	129	SALO et al., "Aminoxy Functionalized Oligonucleotides:Preparation, On-Support Derivitization and Postsynthetic Attachment to Polymer Support," <u>Bioconjugate Chem.</u> 10:815-823 (1999)
	130	SCHNEERSON et al., "Preparation, characterization and immunogenicity of haemophilus influenzae type b polysaccharide-protein conjugates," <u>J. Exp. Med.</u> 152:361-376 (1980)
	131	SEYMOUR et al., "A phase 1 study of BAY 38-3441 given as a short infusion daily for five days every 3 weeks. A National Cancer Institute of Canada Clinical Trials Group Study," <u>Eur. J. Cancer</u> 37(1):73 (2001)
	132	SKOPP et al., "Fingerprinting of proteins cleaved in solution by cyanogen bromide," <u>Appl. Theoret. Electrophoresis</u> 1:61-64 (1989)
	133	SKWARCZYNSKI et al., "Paclitaxel Prodrugs Toward Smarter Delivery of Anticancer Agents," <u>J. Med. Chem.</u> 49(25):7253-7269 (2006)
	134	STIEN et al., "Development and characterisation of novel human multidrug resistant mammary carcinoma lines in vitro and in vivo," <u>Int. J. Cancer</u> 72:885-891 (1997)
	135	SVENSON AND LINDBERG, "Coupling of Acid Labile Salmonella Specific Oligosaccharides to Macromolecular Carriers," <u>J. Immunolog. Meth.</u> 25:323-335 (1979)
	136	SVENSON, "Immunochemistry of Salmonella O-antigens:Preparation of an Octasaccharide-Bovine Serum Albumin Immunogen Representative of Salmonella Serogroup B O-Antigen and Characterization of the Antibody Response," <u>J. Immunol.</u> 120(5):1750-1757 (1978)
	137	Thermo Scientific Pierce, <u>Crosslinking Technical Handbook</u> , 48 pgs. (2009)
	138	TOMASIK et al., "Chemical Modification of Starch," <u>Adv. Carbohydrate Chem. Biochem.</u> , 59:179-403 (2004)

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 14503-0005US1	Application No. 10/567,266
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)  (37 CFR §1.98(b))		Applicant Eichner et al.	
		Filing Date 05-29-2008	Group Art Unit 1623

**Other Documents (include Author, Title, Date, and Place of Publication)**

Examiner Initial	Desig. ID	Document
	139	VASEY et al., :Phase I Clinical and Pharmacokinetic Study of PKI [N-(2-Hydroxypropyl)methacrylamide Copolymer Doxorubicin]:First Member of a New Class of Chemotherapeutic Agents-Drug-Polymer Conjugates," <u>Clin. Cancer Res.</u> 5:83-94, (1999)
	140	WALTZINGER et al., "Pharmacokinetics and Tolerability of a New Hydroxyethyl Starch (HES) Specification [HE (130/0.4)] after Single-Dose Infusion of 6% or 10% Solutions in Healthy Volunteers," <u>Pharmacokinetics</u> 16(2):151-160 (1998)
	141	WANG et al., "Delivery of Antisense Oligonucleotides Using HPMA Polymer:Synthesis of a Thiol Polymer and its Conjugation to Water-soluble Molecules," <u>Bioconj. Chem.</u> 9:749-757 (1998)
	142	ZHANG et al. "Thiazolidine formation as a general and site-specific conjugation method," <u>Anal. Biochem.</u> 233:87-93 (1996)

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	